Brief: Mabpharm Posts FY Loss Attributable Rmb291.7 Million
25/03/2022 15:23
March 25 (Reuters) - Mabpharm:
* FY LOSS ATTRIBUTABLE RMB291.7 MILLION VERSUS LOSS OF
RMB184.6
MILLION
Source text for Eikon: ID:nHKS6PnQ3r
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008